Discover
COYA
Coya Therapeutics, Inc.
4.85
2 x 3.59
2 x 6.16
bid
ask
+
0.00
0.00%
2 @ 04:00 PM
4.85 +0.00 (0.00%)
| Ytd | -16.38% | |
| 1y | -25.38% |
4.74
day range
5.03
3.71
52 week range
7.75
| Open | 4.86 | Prev Close | 4.85 | Low | 4.74 | High | 5.03 | Mkt Cap | 113.77M |
| Vol | 94.62K | Avg Vol | 168.58K | EPS | -1.07 | P/E | N/A | Forward P/E | -4.25 |
| Beta | 0.58 | Short Ratio | 1.53 | Inst. Own | 19.97% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 4.70 | 200-d Avg | 4.73 | 1yr Est | 15.50 |
COYA News
benzinga.com
Coya Therapeutics Announces Full Enrollment Of Planned 120 Participants In Phase 2/3 ALSTARS Trial E
120th participant has been enrolled in ALSTARS trial achieving target enrollmentAdditional eligible
businesswire.com
Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
benzinga.com
BTIG Reiterates Buy on Coya Therapeutics, Maintains $16 Price Target
BTIG analyst Thomas Shrader reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $
benzinga.com
Coya Therapeutics Enrolls 100th Participant In Phase 2/3 ALSTARS Trial Of COYA 302
Based on current screening and enrollment rates, topline data anticipated inearly Q2 2027Additional
benzinga.com
Coya Therapeutics Announces Publication Of Preclinical Results For COYA 303 In International Journal
Study results showed complementary immunomodulatory effects of COYA 303, a combination of proprietar